Key Takeaways
- CDMO top line turns the corner: API prices have stabilized after a multi-year decline, so volume growth now translates into revenue growth; CDMO rose 10% YoY in Q2.
- Jammu is the story: The new facility received its manufacturing license, trial batches are underway, and commercialization begins next month (Q3) with a ~₹500 cr FY26 revenue target.
- Branded generics are running hot: Domestic branded generics delivered the highest-ever quarter at ₹59.1 cr, up 19% YoY, and management expects 20-25%+ growth to continue.
- Margins are improving, with more to come: EBITDA margin expanded 80 bps YoY to 16.3%, helped by mix; Jammu's ramp toward ₹700-900 cr steady-state revenue is the unlock for the 17-19% long-term target.
- What to watch next quarter: The pace of Jammu's commercial ramp, whether the Q4 break-even timeline holds, and any acquisition deployment of surplus cash.
Jammu Facility: The Growth Engine
- License secured, commercialization imminent: The drug manufacturing license from the Jammu & Kashmir Drug Control Organization has been received; manufacturing validation and trial batches have begun, and all four blocks will commence operations together in Q3 (December), not staggered.
- FY26 revenue target: Management expects ~₹400-500 cr in sales next year, based on discussions with marquee customers and a very good response received. The plant is designed to stabilize in Q4 of the current fiscal, giving four full quarters of contribution from Q1 next year.
- Revenue potential: The facility can reach ₹1,200-1,300 cr over the next five years, supporting the company's target to double consolidated revenue from ~₹1,085 cr to ₹2,500 cr in three years (25%+ CAGR).
- Cannibalization is managed, not net-new destructive: The ₹500 cr will be incremental turnover. Domestic cephalosporin business will transfer from Baddi to Jammu, freeing the Baddi cephalosporin facility for export to ROW and regulated markets where capacity was previously constrained.
- Break-even and margin trajectory: The company expects to cross break-even after Q4, with positive EBITDA generation from Q1 next financial year. At ₹400-500 cr revenue, Jammu margins will be in line with company-level margins; at ₹700-800 cr, margin expansion should become visible.
- Interest cost advantage: The Jammu term loan (₹230 cr) carries an interest subvention benefit of up to 6%, so the net landed cost of interest post-commercialization will remain at 2-2.5%.
- Export roadmap: The facility will be registered for export markets across different territories (ROW, semi-regulated, regulated) as time proceeds.
Lohariwala: "But in Jammu, what is the beauty that we have the 12% GST incentive, right? So our expectation is that after Q4, means even in Q4, there may be some lag. But from the Q1 next year, we will be - we will cross the break-even level and start positive EBITDA generation from the Q1 next financial year."
CDMO: The Turnaround Quarter
- Volume growth finally shows up in revenue: CDMO grew 10% YoY in Q2, driven mainly by volume growth with pricing impact neutral YoY. After three years of API price declines compressing the top line despite consistent volume growth, API prices have now normalized and entered stability territory, so revenue growth has resumed.
- The transfer-through model explained: Innova passes API price changes through to customers. When API prices rose during COVID, revenue rose; when they subsequently declined, transfer prices declined and top line fell. Margins were protected throughout because margin is a function of volume, not API price.
- Entry barriers are rising: Revised Schedule M norms impose stricter plant guidelines at par with international standards, requiring large investments (Jammu ~₹450 cr vs initial plant gross block of ₹5-6 cr). Most of Innova's facilities already hold SRA approvals (EUGMP, MHRA, WHO-GMP), so the company views tighter norms as a positive trigger driving industry consolidation toward larger players.
- Consolidation is already underway: Business has been consolidating toward larger players for the last 1-2 years due to Schedule M changes. Management sees acquisition opportunities if a plant is complying and strategically fit, though it declined to confirm any specific instances of smaller players shutting shop.
Lohariwala: "If you see our domestic CDMO business, you will find there are only few companies who have crossed the thousand crores mark, right? So, now as you see that the regulator also has imposed a lot of things like the revised Schedule M and now the pharma plant is like a big investment."
Branded Generics & Sharon: The Steady Compounders
- Domestic branded generics hit a record: The segment delivered its highest-ever quarter at ₹59.1 cr, growing 19% YoY in Q2 and 21% in H1. Growth is a mix of seasonality and organic momentum, and management expects 20-25%+ growth to continue in the near future.
- International branded generics growing rapidly: 13% YoY growth in Q2, 12% in H1. With the Sharon acquisition and Jammu facility registration for exports, the same growth rate is expected to continue.
- Sharon growing, with headroom: Sharon grew 11% YoY in Q2 (H1 revenue ₹97.4 cr). Formulation capacity utilization is at 45-50% vs an optimum of 70-75%, leaving a long ramp-up runway through new customers and new products over the coming years. Growth is expected in the early teens.
- Univentis Medicare as a strategic enabler: The 100% subsidiary is treated as a CDMO customer by Innova and helps in early identification of products, provides market intelligence and market insight, and helps serve CDMO customers better.
Margins & Capital Allocation
- Q2 margin walk: Consolidated EBITDA margin improved 80 bps YoY to 16.3%, driven by product mix and sales mix. PAT grew 52.8% YoY in Q2 (59% in H1), helped by higher EBITDA margins and reduced finance costs.
- Gross margin range holds: Consolidated gross margin improved due to product and sales mix and is expected to remain in the 32-35% range. Management does not track gross margin at the business-area level and declined to comment on competitors' higher gross margins, citing different product sets and market styles.
- Long-term margin target tied to Jammu: At steady state when Jammu is stabilized, management targets EBITDA margins of 17-19%. The positive benefit on margin expansion is expected when Jammu reaches steady-state revenue of ₹700-900 cr.
- Cash deployment priorities: Surplus cash will be deployed toward acquisitions (strategic fit, e.g., hormone or liquid injectable segments where Innova is not present) or a greenfield project.
- GST and interest subvention accounting unresolved: The accounting treatment for GST incentives and interest subvention benefits is still under discussion with statutory auditors and will be accounted per applicable IND-AS standards.
Bhasin: "So the way I am looking at it, so when I am able to reach at a steady-state of Jammu, somewhere in the range of 700 crores to 900 crores, we should be positively looking at a benefit on margin expansion."
Competitive Position & Industry Structure
- Schedule M as a moat-builder: Revised Schedule M creates stricter plant guidelines at par with international standards. Most of Innova's facilities already hold SRA approvals (EUGMP, MHRA, WHO-GMP), so compliance is largely in place. Management sees this as a positive trigger that will further consolidate the industry toward larger players.
- The investment hurdle has risen dramatically: A new pharma plant now requires large investment (Jammu ~₹450 cr vs the initial plant gross block of ₹5-6 cr), plus product dossier and documentation requirements, plus long-term customer relationships built over 5-10 years. Only a few domestic CDMO companies have crossed the thousand-crore revenue mark.
- Competitive philosophy is ROE/ROCE-driven: Management's stated approach is to be competitive for customers while generating good ROE and ROCE for investors, rather than chasing market share or volume at any price.
- Market share data is unavailable: When asked about typical market share for a particular customer or molecule, management stated that detailed CDMO market insight data is not available and the company cannot track the volumes its customers purchase.
Lohariwala: "As most of our facility is having SRA approvals like EUGMP or MHRA or WHO-GMP, so we are complying with all these guidelines. So, we see it as a positive trigger. The industry will further consolidate to the larger players due to this implementation of the sticker norms."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu commercialization | All four blocks commence operations together | Q3 FY25 (December) |
| Jammu break-even | Cross break-even, positive EBITDA generation begins | Q1 FY26 |
| Jammu FY26 revenue | ~₹400-500 cr sales | FY26 |
| Jammu steady-state margin expansion | Positive margin expansion benefit when Jammu reaches ₹700-900 cr revenue | No specific date given |
| Jammu long-term revenue potential | ₹1,200-1,300 cr | Next five years |
| Consolidated revenue target | Double from ~₹1,085 cr to ₹2,500 cr (25%+ CAGR) | Next three years |
| Long-term EBITDA margin | 17-19% at steady state when Jammu is stabilized | When Jammu stabilized |
| Domestic branded generic growth | 20-25%+ growth | Near future |
| Gross margin range | 32-35% | Ongoing |
| Cash deployment | Acquisition (hormone/liquid injectable) or greenfield project | No specific timeline |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated revenue | ₹318.2 cr, +12.5% YoY |
| CDMO revenue | ₹165.1 cr, +10% YoY, volume-driven with stable pricing |
| Domestic branded generic revenue | ₹59.1 cr, +19% YoY, highest-ever quarterly revenue |
| International branded generic revenue | ₹40.5 cr, +13% YoY |
| Sharon revenue | ₹53.6 cr, +11% YoY |
| EBITDA | ₹51.9 cr, +18.6% YoY; margin 16.3%, +80 bps YoY |
| PAT | ₹35 cr, +52.8% YoY; PAT margin 11%, +290 bps YoY |
| H1 FY25 consolidated revenue | ₹612.5 cr, +19% YoY |
| H1 FY25 EBITDA | ₹96.2 cr, +26.2% YoY; margin 15.7% vs 14.8% in H1 FY24 |
| H1 FY25 PAT | ₹64.5 cr, +59% YoY |
| Business mix | CDMO ~52%, Domestic branded generics ~19%, International ~13%, Sharon ~17% |
| Gross margin range (post-consolidation) | 32% to 35%, up from 24% to 28% standalone historically |
| Long-term EBITDA margin target | 17% to 19%, at steady-state with Jammu stabilized |
| Jammu facility capex | ~₹450 cr, CWIP of ₹452 cr as of Sep 30 |
| Jammu facility revenue potential | ₹1,200 cr – ₹1,300 cr over next five years |
| Jammu facility expected FY26 revenue | ₹400 cr – ₹500 cr, incremental to existing business |
| Revenue target (three-year) | ₹2,500 cr, doubling from ~₹1,085 cr, implying ~26% CAGR |
| CDMO client base | 190+ companies, including 14 of top 15 pharma companies |
| Domestic branded generic network | 1.5 lakh touch points, 600+ products |
| International registrations | 148 active, 72 in-process product dossiers across 25+ countries |
| Sharon capacity utilization | 45% to 50% (formulation), optimum range 70% to 75% |
| Jammu term loan | ₹230 cr, net landed interest cost post-commercialization at 2% to 2.5% after 6% interest subvention |
| Jammu GST incentive | 12% on domestic sales, applicable to arm's-length sales including to Univentis |